Filing Flows › Travere Therapeutics (TVTX) › Q1 2026
Travere Therapeutics (TVTX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 4, 2026
Travere Therapeutics (TVTX) reported revenue of $127M for the first quarter 2026 (Q1 2026), +56% from a year earlier and -2% from the quarter before. Operating margin was -29.0%, net loss $37.1M (29.2% of revenue).
Travere Therapeutics, Q1 2026: revenue $127M (+56% year over year), operating margin -29.0%, net loss $37.1M, operating cash flow −$40.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $127M | -2% | +56% |
| Operating profit | −$36.9M | — | — |
| Net earnings | −$37.1M | -1460% | — |
| Operating cash flow | −$40.4M | -167% | — |
What changed
Revenue was $127.2M in Q1 2026, up 56% year over year and down 2% from the previous quarter. FILSPARI was the largest line at 83% of revenue. FILSPARI added $49.3M year over year (up 88%), 108% of the total change. License and collaboration revenue declined 54%.
Operating costs exceeded revenue by $36.9M, an operating margin of -29.0%. Total costs grew 32% against revenue growth of 56%. The fastest-growing cost line was Other operating costs (+100%). The quarter ended with a net loss of $37.1M, after a profit of $2.7M the previous quarter.
Operating cash flow was −$40.4M. Non-cash charges added back $25.2M of depreciation and amortization and $16.1M of share-based compensation. Working capital and other items used $44.6M.
Questions
What was Travere Therapeutics' revenue in the first quarter 2026?
Travere Therapeutics (TVTX) reported revenue of $127M for the first quarter 2026 (Q1 2026), +56% from a year earlier and -2% from the quarter before.
Was Travere Therapeutics profitable in the first quarter 2026?
Operating loss was $36.9M (-29.0% of revenue) and net loss $37.1M.